 
        
            Investor Caution Leads to Dip in Biotech Financings, GlobalData Report Shows
The $6.5 billion raised by biopharmaceutical companies in the first quarter of 2025 is down nearly 20% year over year, according to a report from GlobalData. The firm says investors continue to favor later-stage companies with clinical data. The post Investor Caution Leads to Dip in Biotech Financings, GlobalData Report Shows appeared first on MedCity…
 
                         
                         
                         
                         
                         
                         
         
         
         
         
         
        